# KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer

> **NCT07353645** · PHASE1,PHASE2 · RECRUITING · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 49 (estimated)

## Conditions studied

- Colorectal Cancer
- Pancreatic Cancer

## Interventions

- **DRUG:** KRAS Neoantigen Nanovaccine

## Key facts

- **NCT ID:** NCT07353645
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-23
- **Primary completion:** 2029-01-01
- **Final completion:** 2031-01-01
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07353645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07353645, "KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07353645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*